In January, NASA put out the fiftieth edition of Spinoff, the catalog it has kept since 1976 of technologies that made it out of the lab and into something you can buy, fifty years of things that worked. The same edition mentions that 1,300 inventions are currently sitting in NASA's patent portfolio, available to license.
One of them is a skin that stretches.
NASA built it to stretch more than 20 percent and stay smooth the whole time, with almost no force behind it. Underneath is a honeycomb you can tune: cut the lattice one way and that stretch of it holds firm, cut it another and it gives. The point was to let an aircraft change shape in flight without a seam breaking up the air over the wing.
They published it in January 2007, in NASA Tech Briefs, a magazine that exists to show industry what NASA has. The write-up says what it's for: wings whose planforms change, and flaps that bend without a hinge. Nothing in it mentions a leg.
Eleven years later, four of us, all still students, were badged into a NASA technology transfer office and handed that patent. Our job was to work out what else it could do.
We came back with prosthetic sockets. A socket is the cup that fits over what's left of a limb, and it was then, and mostly still is, hand-molded carbon fiber. It takes a long time to get right and often doesn't: the socket is rigid where a body isn't, and the mismatch cuts sores into skin that has nowhere to go. What it needs is a structure that's stiff in some places and compliant in others, varying along its length, under a surface smooth enough not to pinch. That is the same sentence as the wing.
The market wasn't hard to find either. About two million Americans live with limb loss, a number expected to nearly double by 2050, and a prosthesis runs from about $5,000 to $100,000 and gets replaced every three to five years, sooner for a child who is still growing. The socket was the best of several ideas. We sketched a helmet liner that might blunt a concussion, and proposed the same skin for heart stents until a meta-analysis in JAMA showed stents barely outperform drugs, at which point we dropped it. None of this took special insight, just a semester and a lot of searching.
We handed it to the office, which is what the program was for. Later that year NASA entered the technology in a design contest, listing four applications of its own, prosthetics among them, and took an honorable mention. The patent is still a patent, it has never appeared in Spinoff, and as far as any public record shows nobody has built the socket.
Nobody did anything wrong. The two engineers who invented that skin were doing precisely the job they were hired for, extremely well, and the mandate they were hired under is aerospace. The market question was outside the building.
I do a version of the same work now, eight years later, with Yale faculty trying to turn research into companies, and the problem has a different shape. The science is usually the part that holds up. What's missing is time: the technology is real and early, and it needs to be incubated and tested before anyone will adopt it.
And the person who invented it is a researcher, who can tell you why something works. Whether anyone wants it is a different question, and not one they were ever trained to answer.
So the question gets handed to someone else. Yale's Venture Lab pairs faculty with experienced people out of industry, which is more than most institutions do. But read the description of the associates who conduct the market research and the early customer development, and they are MBA, MPH, PhD, and MD students. I am one of them. We are good at it, and we graduate.
A federal laboratory and an elite university, and the same question unowned in both. At NASA it sat outside the building, unasked for eleven years. At Yale it sits inside the building and gets handed to whoever is passing through, asked constantly by people who leave before they can answer. A patent proves that something is new. It was never built to prove that anyone wants it. Everyone in both buildings is accountable for whether the science is right, and nobody with a title and a reason to still be there in four years is accountable for whether anyone needs it.
But the market question is not even the hard part. We answered it. Four students found the socket in a semester, and still no one built it. The answer changed nothing, because getting a technology from a paper to a product is a long series of handoffs, and no one owns the ones that come after the science: the license, the decade of money it takes to reach a medical device, the FDA, the manufacturer, the patient. At each handoff the same thing is true as at the first. No one whose job outlasts the year is responsible for making sure the next hand is there.
That is why the shelf stays full, and why it is not the free money it looks like. The portfolio is public and there is an API; anyone can read the whole thing in an afternoon. If the value were a search away, it would already be gone. The patent is the easy part. The hard part is owning every handoff between the science and a working product, and almost no one is built to. Venture backs a founder who already owns that. The lab makes the science and stops. In between is a long middle full of value and empty of owners. People notice the patents all the time; carrying one the entire way is a different and much rarer thing than spotting it.
It is an expensive gap to cross at the best of times, and these are not the best of times. The 2026 budget proposal would cut the NIH by about 40 percent and the NSF by 57. We are debating how much less science to buy while the science we already paid for sits in a catalog, finished, with no one to carry it the rest of the way.
The most valuable thing in that catalog was never any single invention. It was the distance no one owns between a finished patent and a working product. Whoever learns to cross it will find most of the competition dropped out somewhere in the middle. The skin is still there. Someone still has to carry it.